It is not recommended for multi-dose vials because it cannot inhibit microbial growth after the first puncture
The C1831 device category was made effective in the OPPS on October 1, 2021, and expired on September 30, 2024, as such, we cannot reinstate the pass-through payment status of C1831 because reinstatement would make the pass-through payment status effective longer than the maximum 3-year period permitted under section 1833(t)(6)(B)(iii) of the Act and 419.66(g)
[DOI] [PubMed] [Google Scholar] le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lnroth H, Fndriks L, Ghatei MA, Bloom SR, 2007
CM-H: Writing original draft
N Engl J Med 334:574579 Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis
NAION is caused by a sudden interruption of blood flow to the optic nerve, leading to rapid, painless, and often irreversible vision loss